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Abstract
Worldwide, approximately one and a half million new cases of lung cancer are diagnosed each year, and about
85% of lung cancer are non-small cell lung cancer (NSCLC). As the molecular pathogenesis underlying NSCLC is
understood, new molecular targeting agents can be developed. However, current therapies are not sufficient to
cure or manage the patients with distant metastasis, and novel strategies are necessary to be developed to cure
the patients with advanced NSCLC.
RNA interference (RNAi) is a phenomenon of sequence-specific gene silencing in mammalian cells and its
discovery has lead to its wide application as a powerful tool in post-genomic research. Recently, short interfering
RNA (siRNA), which induces RNAi, has been experimentally introduced as a cancer therapy and is expected to be
developed as a nucleic acid-based medicine. Recently, several clinical trials of RNAi therapies against cancers are
ongoing. In this article, we discuss the most recent findings concerning the administration of siRNA against polo-
like kinase-1 (PLK-1) to liver metastatic NSCLC. PLK-1 regulates the mitotic process in mammalian cells. These
promising results demonstrate that PLK-1 is a suitable target for advanced NSCLC therapy.
Introduction
Worldwide, approximately one and a half million new
cases of lung cancer are diagnosed each year [1]. About
85% of lung cancer are non-small cell lung cancer
(NSCLC), including adenocarcinoma, squamous cell,
and large cell carcinoma [2], and NSCLC is the leading
cause of cancer-related deaths. Surgery is generally
regarded as the best strategy for lung cancers. However,
only 30% of patients are suitable for receiving potentially
curative resection [3], and it is necessary for other
patients to be treated with chemotherapy. As we gain a
better understanding of the molecular pathogenesis
underlying NSCLC, new molecular targeting agents can
be developed. Tyrosine kinase inhibitors (TKIs) targeting
the epidermal growth factor receptor (EGFR), such as
gefitinib and erlotinib, have shown remarkable activity
in the patients with NSCLC, and particularly these TKIs
are more effective to NSCLC with EGFR mutations in
19 exon (in-frame deletions) and exon 21 (L858R point
mutation), which are found to be more prevalent in
Asian patients [4,5]. However, despite the development
of new TKIs, new mutations in EGFR exon 20, develop-
ing resistance to EGFR TKIs, have emerged in the trea-
ted NSCLC [6,7], and current therapies are not
sufficient to cure or manage the patients with distant
metastasis [8,9]. Therefore, novel strategies are necessary
to be developed so that the patients with NSCLC can be
cured.
RNA interference (RNAi) is a process of sequence
specific post-transcriptional gene silencing induced by
double-strand RNA (dsRNA) and this phenomenon was
discovered in Caenorhabditis elegans (C. elegans) [10].
RNAi has been shown to function in higher organisms
including mammals, and methods that exploit RNAi
mechanisms have been developing. RNAi has now been
well-established as a method for experimental analyses
of gene function in vitro as well as in high-throughput
screening, and recently, RNAi has been experimentally
introduced into cancer therapy. To apply the RNAi phe-
nomenon to therapeutics, it is important to select suita-
ble targets for the inhibition of cancer progression and
also to develop effective drug delivery systems (DDSs).
Recently a lot of useful non-viral DDSs for small inter-
fering RNAs (siRNAs) have been developed [11-17].
Besides selecting suitable targets, an important consid-
eration for siRNA-mediated treatment is to predict and
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avoid off-target effects, which are the silencing of an
unintended target gene, and potential immunostimula-
tory responses. To avoid those effects, the most specific
and effective siRNA sequence must be validated. Modifi-
cation of two nucleosides of the sense strand also com-
pletely co-inhibited the immunological activities of the
antisense strand, while the silencing activity of the
siRNA was maintained [18].
Polo-like kinase-1 (PLK-1) belongs to the family of
serine/threonine kinases and regulates cell division in
the mitotic phase [19,20]. PLK-1 is overexpressed in
many types of malignancies and its overexpression is
associated with poor prognosis of cancer patients
[21,22]. In this review, we discuss possible RNAi strate-
gies against PLK-1 in advanced lung cancers.
Mechanisms of RNAi
The precise mechanisms of RNAi are discussed in sev-
eral reviews [23-25]. In the initiation phase of RNAi
processes, following introduction of dsRNA into a target
cell, dsRNA is processed into shorter lengths of 21-23
nucleotides (nts) dsRNAs, termed siRNAs, by the ribo-
nuclease activity of a dsDNA-specific RNAse III family
ribonuclase Dicer. Dicer consists of an N-terminal heli-
case domain, an RNA-binding Piwi/Argonaute/Zwille
(PAZ) domain, two tandem RNAse III domains, and a
dsRNA-binding domain [26,27]. Mammals and nema-
todes have only a single Dicer, which acts to produce
both siRNAs and miRNAs [28-30], while other organ-
isms have multiple Dicers which perform separate,
specialized functions. Drosophila has two Dicers: Droso-
phila Dicer-1 is required for generating miRNAs,
whereas Drosophila Dicer-2 produces siRNAs [25,31].
dsRNA precursors are sequentially processed by the two
RNAse III domains of Dicer, and cleaved into smaller
dsRNAs with 3’ dinucleotide overhangs [26,32].
In the second effector phase, smaller dsRNAs enter
into an RNA-induced silencing complex (RISC) assem-
bly pathway [33]. RISC contains Argonaute (Ago) pro-
teins, a family of proteins characterized by the presence
of a PAZ domain and a PIWI domain [34]. The PAZ
domain recognizes the 3’ terminus of RNA, and the
PIWI domain adopts an RNAse H-like structure that
can catalyze the cleavage of the guide strand. Most spe-
cies have multiple Ago proteins, but only Ago2 can
cleave its RNA target in humans. The dsRNA is
unwound by ATP-dependent RNA helicase activity to
form two single-strands of RNA. The strand that directs
silencing is called the guide strand, and the other is
called the passenger strand. Ago2 protein selects the
guide strand and cleaves its RNA target at the phospho-
diester bond positioned between nucleotides 10 and 11
[32,35]. The resulting products are rapidly degraded
because of the unprotected ends, and the passenger
strand is also degraded [36,37]. The targeted RNA dis-
sociates from the siRNA after the cleavage, and the
RISC cleaves additional targets, resulting in decrease of
expression of the target gene (Figure 1) [38].
Polo-like kinase-1
To develop RNAi therapy against cancers, it is essential
that suitable gene targets are selected. Such targets
include antiapoptotic proteins, cell cycle regulators,
transcription factors, signal transduction proteins, and
factors associated with malignant biological behaviors of
cancer cells. All of these genes are associated with the
poor prognosis of cancer patients. PLKs belong to the
family of serine/threonine kinases and are highly con-
served among eukaryotes. PLK family has identified
PLK-1, PLK-2 (SNK), PLK-3 (FNK), and PLK-4 (SAK)
in mammalians so far and PLKs function as regulators
of both cell cycle progression and cellular response to
DNA damage [19,39-41]. PLK-1 has an N-terminal ser-
ine/threonine protein kinase domain and two polo box
domains at the C-terminal region. Polo box domains
regulate the kinase activity of PLK-1 [21,42]. PLK-1 reg-
ulates cell division at several points in the mitotic phase:
mitotic entry through CDK1 activation, bipolar spindle
formation, chromosome alignment, segregation of chro-
mosomes, and cytokinesis [19,43]. PLK-1 gene expres-
sion is regulated during cell cycle progression, with a
peak level occurring at M phase. Similar to its gene
expression, PLK-1 protein expression and its activity are
low in G0, G1, and S phases, and begin to increase in
G2 phase with peak in M phase [44-47].
Whereas PLK-1 is scarcely detectable in most adult
tissues [45,48,49], PLK-1 is overexpressed in cancerous











Figure 1 Mechanisms of RNA interference. After the introduction
of dsRNA into a target cell, the dsRNA is processed into siRNA
length of 21-23 nucletides by Dicer. siRNA then enters an RNA-
induced silencing complex (RISC) assembly pathway. The dsRNA
unwinds to form two single-strands of RNA. The passenger strand
rapidly degrades and the guide strand binds and cleaves the target
mRNA, resulting in mRNA degradation.
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histological grades of tumors, clinical stages, and prog-
nosis of the patients. PLK-1 mRNA levels were elevated
in NSCLC tissues and this transcript levels were corre-
lated with the survivals of cancer patients [50]. More-
over, the immunohistoligical study showed that PLK-1
protein was overexpressed in NSCLC tissues in patients
at progressed stages of cancer (postsurgical stage ≥II)
and in patients with poorly differentiated NSCLCs [51].
Patients with urinary bladder cancers expressing high
levels of PLK-1 have a poor prognosis compared with
patients with its low expression. Moreover, the histologi-
cally high-grade, deeply invasive, lymphatic-invasive, and
venous-invasive bladder cancers demonstrated signifi-
cantly higher PLK-1 expression [52]. As PLK-1 is over-
expressed in other various cancers [21], PLK-1
overexpression is a prognostic biomarker for cancer
patients.
Inhibition of PLK-1 activity induces mitotic arrest and
tumor cell apoptosis [53-55]. Depletion of PLK-1 mRNA
also inhibits the functions of PLK-1 protein in DNA
damages and spindle formation and causes the inhibition
of the cell proliferation in a time- and a dose-dependent
manner. PLK-1 siRNA treatment induces an arrest at the
G2/M phase in the cell cycle with the increase of CDC2/
Cyclin B1 [51,52,56,57]. PLK-1 siRNA-transfected cells
had dumbbell-like and misaligned nuclei, indicating that
PLK-1 depletion induced abnormalities of cell division
during M phase, and these cells were shown to yield to
caspase-dependent apoptosis [51,52,56]. As mentioned
above, the kinases of PLK family cooperatively act in
mitosis. Quantitative real-time RT-PCR data showed that
PLK-2 and PLK-3 transcripts were increased after PLK-1
siRNA treatment [51]. Unlike PLK-1, PLK-2 and PLK-3
play inhibitory roles. PLK-2 is regulated by p53 and PLK-
3 is activated by the DNA damage checkpoint [40]. These
observations suggest that PLK-1 depletion induced mito-
tic catastrophe and activation of spindle checkpoint and
DNA damage checkpoint, resulting in increased tran-
scription of PLK-2 and PLK-3. Consequently, these PLK
family kinases cooperatively prevented G2/M transition
and induction of apoptosis. Importantly, depletion of
PLK-1 does not affect the proliferation of normal cells
although PLK-1 plays an important role in cell division
[51,53,58]. This suggests that some other kinases com-
pensate loss of PLK-1 function during mitosis in normal
cells [51,58]. Collectively, PLK-1 could be an excellent
target for cancer therapy.
Atelocollagen
Although siRNA target molecules are overexpressed in
cancer cells, most of them are essential to maintain
homeostasis of physiological functions in humans.
Therefore, siRNAs must be delivered selectively into
cancer cells. Moreover, naked siRNAs are degraded by
endogenous nucleases when administered in vivo, so that
delivery methods that protect siRNAs from such degra-
dation are essential. For these reasons, safer and more
effective DDSs must be developed. DDSs are divided into
two categories: viral vector based carriers, and non-viral
based carriers. Viral vectors are highly efficient delivery
systems and they are the most powerful tools for trans-
fection so far. However, viral vectors have several critical
problems in in vivo application. Especially, retroviral and
lentiviral vectors have major concerns of insertional
mutagenesis [59,60]. Consequently, non-viral DDSs have
been strenuously developed [11-13].
Atelocollagen, one of powerful non-viral DDSs, is type
I collagen obtained from calf dermis [61]. The molecular
weight of atelocollagen is approximately 300,000 and the
length is 300 nm. It forms a helix of 3 polypeptide
chains. Amino acid sequences at the N- and C-termini
of the collagen molecules are called telopeptide, and
they have antigenecity of collagen molecules. As the tel-
opeptide is removed from collagen molecules by pepsin
treatment, atelocollagen shows low immunogenicity.
Therefore, atelocollagen has been shown to be a suitable
biomaterial with an excellent safety profile and it is used
clinically for a wide range of purposes. Atelocollagen is
positively charged, which enable binding to negatively
charged nucleic acid molecules, and bind to cell mem-
branes. Moreover, at low temperature atelocollagen
exists in liquid form, which facilitates easy mixing with
nucleic acid solutions. The size of the atelocollagen-
nucleic acid complex can be varied by altering the ratio
of siRNA to atelocollagen. Because atelocollagen natu-
rally forms a fiber-like structure under physiological
conditions, particles formed a high concentration of ate-
locollagen persist for an extended period of time at the
site of introduction, which is advantageous to achieve a
sustained release of the associated nucleic acid. Atelo-
collagen is eliminated through a process of degradation
and absorption similar to the metabolism of endogenous
collagen [61]. Alternatively, particles formed under con-
ditions of low atelocollagen concentrations result in
siRNA/atelocollagen complexes approximately 100-300
nm in size that are suitable for systemic delivery by
intravenous administration. Atelocollagen complexes
protect siRNA from degradation by nucleases and are
transduced efficiently into cells, resulting in long-term
gene silencing. For instance, Takeshita et al. demon-
strated that the systemic siRNA delivery with atelocolla-
gen existed intact for at least 3 days in tumor tissues
using a mouse model [62].
Preclinical application of RNAi therapy against PLK-1 in a
murine advanced lung cancer model
Here we introduce an application of PLK-1 siRNA
against an advanced lung cancer. As described above,
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PLK-1 is overexpressed in NSCLC tumors. Liver metas-
tasis is one of the most important prognostic factors in
lung cancer patients [8,9,63,64]. However, despite the
development of new chemotherapeutic and molecular
targeting agents, current therapies are not sufficient to
inhibit liver metastasis. We investigated the effects of
PLK-1 siRNA on the liver metastasis of lung cancers
using atelocollagen as a DDS. We first established a
mouse model of liver metastasis. Spleens were exposed
to allow direct intrasplenic injections of Luciferase
(Luc)-labeled A549 NSCLC cells. Ten minutes after
injections of tumor cells, the spleens were removed.
After Luc-labeled A549 cell engraftment was confirmed
by using In Vivo Imaging System (IVIS) of biolumines-
cence imaging [65], PLK-1 siRNA/atelocollagen com-
plex, nonsense siRNA/atelocollagen complex, or PBS/
atelocollagen complex was administered by intravenous
injection for 10 consecutive days following day 1 of
transplantation. On day 35, mice treated with nonsense
siRNA/atelocollagen complex or PBS/atelocollagen com-
plex showed extensive metastases in the liver when
compared to mice treated with PLK-1 siRNA/atelocolla-
gen complex (Figure 2). Moreover, on day 70 after the
inoculation of tumor cells, livers of mice treated with
nonsense siRNA/atelocollagen or PBS/atelocollagen
complex had numerous large tumor nodules, whereas
the livers of mice treated with PLK-1 siRNA/atelocolla-
gen complex showed a much lower number of smaller
nodules. These findings indicate that PLK-1 siRNA/ate-
locollagen complex is an attractive therapeutic tool for
further development as a treatment against liver metas-
tasis of lung cancer [51]. Consequently, our preclinical
applications suggest that PLK-1 siRNA is a promising
tool for cancer therapy.
Conclusion
Our preclinical studies demonstrated that RNAi therapy
against PLK-1 using atelocollagen is effective against liver
metastatic NSCLC cancers. Recently, several clinical trials
for cancer therapy are ongoing (Additional file 1: Table
S1, http://clinicaltrials.gov/ct2/home). Although RNAi
shows excellent specificity in gene-silencing, several
adverse effects including activation of immune reaction
[66,67] and off-target effects (induction of unintended
gene silencing) [68] are brought in in vivo application.
Safer and more efficient DDSs for systemic delivery are
warranted to be developed. Moreover, studies to establish
the pharmacokinetics and pharmacodynamics of siRNAs
on the administration are necessary steps in the potential
approval of siRNA as a tool for cancer therapy. To maxi-
mize efficacy and to minimize adverse effects of RNAi, it
should be determined whether siRNAs are best adminis-
tered alone or in combination with chemotherapeutic
agents [69,70], and whether it is better to administer a
single specific siRNA or multiple specific siRNAs
[57,71-73]. In conclusion, RNAi therapy represents a
powerful strategy against advanced lung cancers and may
offer a novel and attractive therapeutic option. The suc-
cess of RNAi depends on the suitable selection of target
genes and the development of DDSs. We anticipate that
the continued development of effective DDSs and the
accumulation of evidence further proving the success of
siRNA treatment will advance RNAi as a promising strat-
egy for lung cancer therapy.
Additional material
Additional file 1: Table S1 Clinical trials of RNAi.
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Figure 2 Application of PLK-1 RNAi therapy against liver
metastatic NSCLC (cited from [51]). A. PBS/atelocollagen complex,
nonsense siRNA/atelocollagen complex, or PLK-1 siRNA/
atelocollagen complex was administered by intravenous injection.
Representative mice showing bioluminescence after siRNA
treatment. The photon counts of each mouse are indicated by the
pseudocolor scales. B. Growth curves of inoculated Luc-labeled
A549 cells measured by the IVIS (pink square, nonsense siRNA/
atelocollagen complex (25 μg siRNA)-treated mice; blue diamond,
PBS/atelocollagen complex-treated mice; orange triangle, PLK-1
siRNA/atelocollagen complex (25 μg siRNA)-treated mice; n = 5 for
each group. On day 35 after inoculation, the luminesecence in the
PLK-1 siRNA/atelocollagen-treated mice was significantly suppressed
compared with that in other groups. * p < 0.05. Mean ± SD. C.
Macroscopic analysis of mice livers after day 70 of inoculation.
White nodules are metastatic liver tumors. Treatment with PLK-1
siRNA (25 μg) remarkably inhibited the growth of liver metastases
compared with PBS or nonsense siRNA treatments (25 μg).
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